Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892281 · ClinicalTrials.gov registry record · Phase 4
ORCA - Oracea® for Rosacea: A Community-based Assessment
A Phase 4 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,421
- Enrollment target
- 1
- Study location
NCT00892281: Completed Phase 4 study of Rosacea, sponsored by Galderma R&D.
NCT00892281 is a Phase 4 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 1,421 participants, above the 181-participant average among 23 other Rosacea trials with a reported enrollment target (685% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892281, a Phase 4 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,421 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
Primary Outcome
Number of participants with a change (Week 12 minus Baseline) in Investigator's Global Assessment (IGA) score. IGA is measured on a scale from 0 - 4 with 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12.
Conditions Studied
Interventions
- DRUG doxycycline (Oracea®) 40 mg modified release as monotherapy
- DRUG doxycycline (Oracea®) 40 mg modified release as add-on therapy
Study Locations (1)
Kentucky
- REGISTRAT® - MAP1, Inc. (CRO) - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,421 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
What the finished NCT00892281 record still lists
NCT00892281 is an interventional study that assigns participants to a tested intervention. Its 1,421 participants enrollment target places it among the larger protocols in the corpus, above the 181-participant average among 23 other Rosacea trials with a reported enrollment target (685% higher).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which doxycycline (Oracea®) 40 mg modified release as monotherapy is the first listed.
NCT00892281 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00892281 about?
NCT00892281 is a clinical study titled "ORCA - Oracea® for Rosacea: A Community-based Assessment". The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
What is the current status of trial NCT00892281?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,421 participants. The study started on 2009-04. Estimated completion is 2009-10.
What conditions does trial NCT00892281 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT00892281?
The interventions under investigation include: doxycycline (Oracea®) 40 mg modified release as monotherapy (DRUG), doxycycline (Oracea®) 40 mg modified release as add-on therapy (DRUG).
Who is sponsoring clinical trial NCT00892281?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892281 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00892281's enrollment target sits among peer trials
1,421 1st of 23 higher than 23 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
COMPLETED · Phase 4
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Analysis of the Microbiome in Rosacea
ACTIVE NOT RECRUITING · Early Phase 1
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia